• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
177003 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
: |4 Y7 |" N( Z5 W
) w+ i# \+ K- K( H4 |) v
8 ]) u( a+ L0 s& }* Q0 [Sub-category:
9 l( ]0 b5 [& b1 R' zMolecular Targets
2 _8 E' P. b4 \( l6 B  H3 N; ?9 Y1 R+ K& k/ U" U$ l' T0 l. o6 y7 i
1 {' L- [$ i# Y: _% U1 R
Category:
; O5 e1 a3 g( V7 E; R; l% VTumor Biology
( h) b2 W7 Y5 W, {% Z. d
! N- r) _% D0 ~0 l0 S" l
  b$ D8 _8 k8 ]% kMeeting:+ k1 z" I, B  d4 _; {
2011 ASCO Annual Meeting ( P$ }" m* I6 d$ ^

/ M* U( S# V/ O: J+ r! L3 Y' |/ S8 n
Session Type and Session Title:# l  n! j( |& \% m& z) v" S% g
Poster Discussion Session, Tumor Biology
1 v  R5 n( z6 L+ |6 o: t& p( O5 P9 d7 i7 ~) P! v

" J% P, ]! x/ t  _) C, P. s0 tAbstract No:
( }( Y4 b1 y) Z10517
/ c4 w' k+ s5 m2 @' Y0 k- Y# }5 K- Q! V
6 _$ R/ J; Q8 `% ^/ o$ x6 K# H  J/ Y$ x" I+ d* T
Citation:
. z* q" L. {" R: eJ Clin Oncol 29: 2011 (suppl; abstr 10517)
1 a. o" U/ M3 w- s% j
8 U2 D. T0 y) F% w- z7 P+ o- n- `& }
( a- K5 ], P2 A" b/ W; P* wAuthor(s):
2 Z6 d% m( C2 U# G6 {  {J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
& a4 M2 z$ V0 p1 g# U" g0 V3 Y2 L: P1 U
3 s  h/ V: O% \- Z( k- h
2 t' e  R; q+ h4 ^' B$ T9 V# Y% r. q
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! U9 o5 W& r4 |9 K7 b! O& d2 g

" J* X2 v' M  oAbstract Disclosures6 D1 Z9 W; b8 g0 A2 N

8 B: }  x7 j( n, JAbstract:
4 a! ~! ?, h3 S# j) j9 ?4 P+ }  E/ O% L# s6 K
- o  E* y* c+ C: H
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.' B: e6 t% M, v4 m# r' l. s
; U6 c, j3 c, f3 L, f% S; O

' K% x# }: D" y0 G9 B" y" f6 E5 z
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 6 A7 v6 Z+ _# \6 c2 g: T6 L" ~# o
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

/ t, B$ c/ W  {化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - b' u( s' R4 x5 Q' d
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
- S3 R% {# Z( j4 @- W6 y1 `ALK一个指标医院要900多 ...

0 m5 d1 E9 B* r$ d9 n0 d平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?( X: H4 m4 P' O) m, X4 V
4 Q2 C- N* _+ p( k
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表